Attached files

file filename
EX-31.1 - CERTIFICATIONS - ETERNITY HEALTHCARE INC.f10q0713ex31i_eternityhealth.htm
EX-32.1 - CERTIFICATIONS - ETERNITY HEALTHCARE INC.f10q0713ex32i_eternityhealth.htm
EXCEL - IDEA: XBRL DOCUMENT - ETERNITY HEALTHCARE INC.Financial_Report.xls


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q

(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the quarterly period ended
July 31, 2013
   
or
 
o
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the transition period from
 
     to
 
       
Commission File Number
000-53376
 
ETERNITY HEALTHCARE INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
75-3268426
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)
     
8755 Ash Street, Suite 1, Vancouver, British Columbia
 
V6P 6T3
(Address of principal executive offices)
 
(Zip Code)
 
(855) 324-1110 

(Registrant’s telephone number, including area code)
 
N/A

(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
x
YES
o
NO
       
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
x
YES
o
NO
         
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company.  See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer
o
(Do not check if a smaller reporting company)
Smaller reporting company
x
         
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act
             
o
YES
x
NO
 
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
 
Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.
 
             
o
YES
o
NO
 
APPLICABLE ONLY TO CORPORATE ISSUERS
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
66,299,868 common shares issued and outstanding as of September 16, 2013.
 


 
 

 
 
TABLE OF CONTENTS
 
 
 
2

 
 
 
 
The following unaudited interim condensed consolidated financial statements of Eternity Healthcare Inc. for the three month period ended July 31, 2013 are included with this Quarterly Report on Form 10-Q.
 
 
3

 
 
 
 
 
 
 
 
Eternity Healthcare Inc.
(A Development Stage Company)
CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
For the three months ended July 31, 2013 and 2012
(Expressed in U.S. Dollars)
 
 
 
 
 
 
 
 
 
 
 
 
 
4

 
 
NOTICE TO READER

On the basis of information provided by management, we have compiled the condensed consolidated balance sheet of Eternity Healthcare Inc. (Expressed in U.S. Dollars) as at July 31, 2013 and 2012 and the condensed consolidated statements of loss, deficit and accumulated other comprehensive income (loss) and cash flows for the three month periods then ended.

We have not performed an audit or a review engagement in respect of these condensed consolidated financial statements and, accordingly, we express no assurance thereon.

Readers are cautioned that these condensed consolidated financial statements may not be appropriate for their purposes.

Vancouver, B.C.
   
September 3, 2013
 
Chartered Accountants

 
5

 

Eternity Healthcare Inc.
(A Development Stage Company)
CONDENSED CONSOLIDATED BALANCE SHEET
(Expressed in U.S. Dollars)

 
   
As at
July 31, 2013
   
As at
April 30, 2013
 
             
ASSETS
           
             
CURRENT ASSETS
           
Cash and cash equivalents
  $ 615,668     $ 156,554  
Accounts receivable
    4,134       297  
Inventory (Note 5)
    42,275       12,822  
Prepaid expenses
          16,038  
GST/HST receivable
    5,108       3,729  
      667,185       189,440  
                 
PROPERTY AND EQUIPMENT, net (Note 6)
    104       165  
                 
TOTAL ASSETS
  $ 667,289     $ 189,605  
                 
LIABILITIES
               
                 
CURRENT LIABILITIES
               
Accounts payable and accrued liabilities
  $     $ 4,532  
Due to related parties (Note 7)
    845,467       762,679  
                 
Total Liabilities
    845,467       767,211  
                 
SHAREHOLDERS’ DEFICIENCY
               
                 
CAPITAL STOCK (Note 8)
               
                 
Authorized
               
300,000,000 common shares, par value $0.001
               
Issued and outstanding
               
July 31, 2013 – 63,575,000 common shares
               
April 30, 2013 – 63,575,000 common shares
    63,575       63,575  
Additional paid-in capital
    (63,180 )     (73,816 )
Share subscriptions (Note 10)
    461,620        
Accumulated other comprehensive gain (loss)
    9,565       310  
Deficit, accumulated during the development stage
    (649,758 )     (567,675 )
                 
Total Stockholders’ deficiency
    (178,178 )     (577,606 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
  $ 667,289     $ 189,605  
 
The accompanying notes are an integral part of these interim consolidated financial statements.
 
 
6

 
 
Eternity Healthcare Inc.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF LOSS AND COMPREHENSIVE LOSS
(Expressed in U.S. Dollars)

 
   
For the
three month
period
ended
July 31, 2013
   
For the
three month
period
ended
July 31,2012
   
From
inception on
December
10, 2009 to
July 31, 2013
 
                   
SALES
                 
Product sales
  $ 19,091     $     $ 35,266  
Cost of goods sold
    4,992             10,625  
              Gross margin
    14,099             24,641  
                         
EXPENSES
                       
Depreciation
    61       61       623  
General and administrative
    29,971       14,229       161,252  
Professional fees
    35,278       15,340       328,489  
Research and development
                109,360  
Salaries
    30,872             74,675  
                         
NET LOSS FROM OPERATIONS
  $ (82,083 )   $ (29,630 )   $ (649,758 )
                         
Provision for income taxes
                 
                         
NET LOSS
  $ (82,083 )   $ (29,630 )   $ (649,758 )
                         
OTHER COMPREHENSIVE INCOME
                       
Foreign currency translation adjustments
    9,255       7,816       9,565  
                         
COMPREHENSIVE LOSS
  $ (72,828 )   $ (21,814 )   $ (640,193 )
                         
COMPREHENSIVE LOSS PER SHARE – BASIC AND DILUTED
  $ (0.001 )   $ (0.000 )        
                         
NET LOSS PER SHARE – BASIC AND DILUTED
  $ (0.001 )   $ (0.000 )        
                         
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
    63,575,000       63,575,000          
 
The accompanying notes are an integral part of these interim consolidated financial statements.
 
 
7

 

Eternity Healthcare Inc.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Expressed in U.S. Dollars)

 
   
For the
 three month
period
ended
July 31,2013
   
For the
three month
period
ended
July 31, 2012
   
From
inception on
December
10, 2009 to
July 31, 2012
 
                   
OPERATING ACTIVITIES
                 
                   
Net (loss) income for the period
  $ (82,083 )   $ (29,630 )   $ (649,758 )
Adjustments to reconcile net cash provided by operating activities:
                       
    Depreciation
    61       70       623  
Expenses paid on behalf of the Company by related parties
                7,308  
Stock options issued for services
    10,636             22,893  
Changes in operating assets and liabilities:
                       
Inventory
    (29,453 )           (42,275 )
Prepaid expenses
    16,038               
Accounts receivable
    (3,843 )           2,293  
Accounts payable and accrued liability
    (4,445 )     (3,642 )     (4,742 )
GST/HST receivable
    (1,451 )     2,275       (5,479 )
                         
Net cash used in operating activities
    (94,540 )     (35,486 )     (669,137 )
                         
INVESTING ACTIVITIES
                       
Purchase of equipment
                (727 )
                         
FINANCING ACTIVITIES
                       
Common shares issued for cash
                380  
Subscription payments received
    461,620        —       461,620  
Proceeds from related party payables
    97,350       36,109       881,209  
Repayments on related party payables
                (31,673 )
                         
Net cash provided by financing activities
    558,970       36,109       1,311,536  
                         
EFFECT OF EXCHANGE RATE CHANGES ON CASH
    (5,316 )     (5,125 )     (26,014 )
                         
INCREASE (DECREASE) IN CASH
    459,114       (4,502 )     615,658  
                         
CASH, beginning of period
    156,554       226,372        
                         
CASH, end of period
  $ 615,668       221,870     $ 615,658  
                         
NON CASH INVESTING AND FINANCING ACTIVITIES
                       
   Net assets acquired in share agreement
                22,879  
 
The accompanying notes are an integral part of these interim consolidated financial statements.
 
 
8

 

Eternity Healthcare Inc.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Expressed in U.S. Dollars)
(Unaudited)

 
   
 
Shares
   
 
Amount ($0.001 par)
   
Additional paid-in capital
   
Share subscriptions
   
Accumulated OCI
   
Accumulated deficit
   
 
Total
 
                                           
Balance as at April 30, 2010
    60,000,000       60,000       (59,620 )           (914 )     (29,765 )     (30,299 )
                                                         
Recapitalization (Notes 1 and 6)
    3,575,000       3,575       (26,453 )                       (22,878 )
                                                         
Currency translation adjustment
                            3,543             3,543  
                                                         
Net loss for the year ended April 30, 2011
                                  (101,221 )     (101,221 )
                                                         
Balance as at April 30, 2011
    63,575,000       63,575       (86,073 )           2,629       (130,986 )     (150,855 )
                                                         
Currency translation adjustment
                            (12,143 )           (12,143 )
                                                         
Net loss for the year ended April 30, 2012
                                  (184,650 )     (184,650 )
                                                         
Balance as at April 30, 2012
    63,575,000     $ 63,575     $ (86,073 )         $ (9,514 )   $ (315,636 )   $ (347,648 )
                                                         
Value options issued for shares
                12,257                         12,257  
                                                         
Currency translation adjustment
                              9,824             9,824  
                                                         
Net loss for the period ended April 31, 2013
                                  (252,039 )     (252,039 )
                                                         
Balance as at April 30, 2013
    63,575,000     $ 63,575     $ (73,816 )         $ 310     $ (567,675 )   $ (577,606 )
                                                         
Value options issued for shares
                10,636                         10,636  
                                                         
Issuance of subscriptions on private placement (Note 10)
                    $ 461,620                   461,620  
                                                         
Currency translation adjustment
                            9,255               9,255  
                                                         
Net loss for the period ended July 31, 2013
                                  (82,083 )     (82,083 )
      63,575,000     $ 63,575     $ (63,180 )     461,620     $ 9,565     $ (649,758 )   $ (178,178 )

The accompanying notes are an integral part of these interim consolidated financial statements.
 
 
9

 

Eternity Healthcare Inc.
(A Development Stage Company)
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2013
(Expressed in U.S. Dollars)
(Unaudited)

 
1.         NATURE AND CONTINUANCE OF OPERATIONS

Eternity Healthcare Inc. (the “Company”) was incorporated under the laws of the State of Nevada on October 24, 2007 under the name Kid’s Book Writer, Inc.  On September 23, 2010, the Company changed its name to Eternity Healthcare Inc., and affected a reverse stock split of the issued and outstanding common stock at a factor of 10 old shares for 1 new share.  The Company is focused on offering an extensive range of diagnostic kits, general lifestyle supplements and many other management products and resources.

On December 13, 2010, pursuant to the terms of a share exchange agreement, the Company acquired 100% of the issued and outstanding common stock of Eternity Healthcare Inc., a company incorporated under the laws of the Province of British Columbia on December 10, 2009 (“Eternity BC”), for 60,000,000 shares of its own common stock, which were distributed to the shareholders of Eternity BC (the “Share Exchange Agreement”) (Note 7).

The Share Exchange Agreement, which represents a majority of the then issued and outstanding shares of the Company, constituted a change in control of the Company.  The acquisition of Eternity BC was accounted for as a reverse acquisition in accordance with Accounting Standards Codification (“ASC”) 805-40, “Business Combinations”.  The Company determined for accounting and reporting purposes that Eternity BC is the acquirer because of the significant holdings and influence of the control group of the Company before and after the acquisition.  As a result of the transaction, Eternity BC shareholders own approximately 94.4% of issued and outstanding common stock of the Company on a diluted basis.

Accordingly, the assets and liabilities of Eternity BC are reported as historical costs and the historical results of operations of Eternity BC are reflected in this and future filings as a change in reporting entity.  The assets and liabilities of the Company are reported at their carrying values, which approximate fair value, on the date of the acquisition and results of operations are reported from the date of acquisition of December 13, 2010.  The transaction was accounted for as a recapitalization of Eternity BC and the issuance of stock by Eternity BC for the assets and liabilities of the Company.

The Company is a development stage enterprise, as defined in ASC 915-10 “Development Stage Entities”.  The Company is devoting all of its present efforts in securing and establishing a new business, and its planned principle operations have not commenced, and, accordingly, a small amount of revenue has been derived during the organization period.

On June 25, 2012, the Company entered into a marketing agreement with Mika Medical Company of Korea, to be the sole marketer of a new line of needle-free injection product for North America.  Furthermore, the marketing agreement was extended to some European countries (Germany, France and Spain) in December 2012.  Additionally, the Company obtained the rights to market the products throughout the world with an Amendment dated December 20, 2012.

Since signing the Distribution Agreement with Mika Medicals, the Company has emerged in organizational and start-up activities, including developing a new business plan, making arrangements for office space and raising additional capital.  The Company has generated a small amount of revenue from product sales.
 
 
10

 

Eternity Healthcare Inc.
(A Development Stage Company)
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2013
(Expressed in U.S. Dollars)
(Unaudited)

 
1.         NATURE AND CONTINUANCE OF OPERATIONS - continued

The Company’s consolidated financial statements as at July 31, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business.  The Company has net loss of $82,083 for the quarter ended July 31, 2013 (July 31, 2012 - $29,526) and has a working capital deficit of $ 178,282 as at July 31, 2013 (April 30, 2013 - $577,771).

2.         CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, result of operations, and cash flows at July 31, 2013, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s April 30, 2013 audited financial statements. The results of operations for the period ended July 31, 2013 and 2012 are not necessarily indicative of the operating results for the full year.
 
3.         GOING CONCERN

The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

4.         SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements.

Basis of presentation
These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in U.S. dollars.

Principles of consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Eternity BC.  All significant intercompany balances and transactions have been eliminated in consolidation.
 
 
11

 
 
Eternity Healthcare Inc.
(A Development Stage Company)
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2013
(Expressed in U.S. Dollars)
(Unaudited)

 
4.         SIGNIFICANT ACCOUNTING POLICIES - continued

Cash and cash equivalents
Cash and cash equivalents include highly liquid investments with original maturities of three months or less.

Inventory
Inventory is stated at the lower of cost or market with cost determined under the weighted average cost method
 
Foreign currency translation
The Company’s functional currency is the Canadian dollar and reporting currency is the U.S. dollar.  All transactions initiated in other currencies are translated into the reporting currency in accordance with ASC 830, “Foreign Currency Matters” as follows:

            i)   Assets and liabilities at the rate of exchange in effect at the balance sheet date; and
            ii)   Revenue and expense items at rate of exchange at the dates on which those elements are recognized.

Gains and losses on translation are included in other comprehensive income (loss) in stockholders’ deficiency for the period.

Basic and diluted net income (loss) per share
The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”.  ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.  Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period.  Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method.  In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.  Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

Use of estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenditures during the reporting period.  Actual results could differ from these estimates

Recent accounting pronouncements
The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have material impact on the Company’s financial position or statements.
 
 
12

 

Eternity Healthcare Inc.
(A Development Stage Company)
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2013
(Expressed in U.S. Dollars)
(Unaudited)

 
5.         INVENTORY

Inventory consists of needle free injection products that are held for resale.  Inventory is stated at the lower of cost or market with cost determined under the weighted average cost method.  As of July 31, 2013 and April 30, 2013 inventory consisted of the following:
 
   
July 31,
   
April 30,
 
   
2013
   
2013
 
             
Raw materials
  $     $  
Work in progress
           
Finished goods
    42,275       12,822  
Reserve for obsolescence
           
    $ 42,275     $ 12,822  
 
6.         EQUIPMENT
 
         
Accumulated
   
July 31,
   
April 30
 
   
Cost
   
depreciation
   
2013
   
2013
 
                         
Computer equipment
  $ 727     $ 623     $ 104     $ 165  
 
7.         DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS

During the period ended July 31, 2013, the Company received $97,350 in additional cash loans from a related party of the Company.  Total related party notes payable as of July 31, 2013 were $845,467.  This balance is non-interest bearing, unsecured and has no fixed terms of repayment.

See also Note 10.

8.         CAPITAL STOCK

Authorized
The total authorized capital is 300,000,000 common shares with a par value of $0.001 per common share.

Issued and outstanding
Effective on November 1, 2010, the Board of Directors approved a 1:10 reverse stock split and decreased the issued and outstanding share capital from 35,750,000 to 3,575,000 with the same par value of $0.001 per share.  Unless otherwise noted, all references herein to the number of common shares, price per common share or weighted average number of common shares outstanding have been adjusted to reflect this reverse stock split on a retroactive basis.

On December 13, 2010, the Company issued 60,000,000 common shares of the Company with a value of $60,000 related to the Share Exchange Agreement (Note 1).

See also Note 10.
 
 
13

 

Eternity Healthcare Inc.
(A Development Stage Company)
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
July 31, 2013
(Expressed in U.S. Dollars)
(Unaudited) 


9.         STOCK OPTIONS

During the fiscal year ended April 30, 2013, the Company granted 200,000 stock options for services.  The fair value of the stock options granted were estimated on the date granted using the Black-Scholes pricing model, with the following assumptions used for the valuation: exercise price of $0.55 per share, average risk-free interest rate of 0.79%, expected dividend yield of zero, expected lives of five years and an average expected volatility of 2.99%.  During the three months ended July 31, 2013 and 2012, the Company recognized expense of $10,636 and $Nil related to options that vested, respectively.

During the period ended July 31, 2013, the Company issued no new stock options.

10.       SUBSEQUENT EVENT

Subsequent to the end of the quarter the Company completed an agreement with existing shareholders to exchange outstanding loans to related parties for common shares at a rate of 1 common share per $0.50 of debt. The total number of shares issued under this agreement was 1,724,868 to settle amounts due to related parties of $862,434.

Additionally, the Company completed a non-brokered private placement for 1,000,000 common shares at a price of $500,000, of which $461,620 was received by July 31, 2013.
 
 
14

 

 
Forward-Looking Statements
 
This quarterly report on Form 10-Q and other reports filed by our company from time to time with the United States Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements (collectively the “Filings”) and information that are based upon beliefs of, and information currently available to, our company’s management as well as estimates and assumptions made our company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the filings, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions as they relate to our company or our company’s management identify forward-looking statements. Such statements reflect the current view of our company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks contained in the “Risk Factors” section of our company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2012, filed with the SEC, relating to our company’s industry, our company’s operations and plan of operations, and any businesses that our company may acquire. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.
 
Although we believe that the expectations reflected in the forward-looking statements are reasonable, our company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, our company does not intend to update any of the forward-looking statements to conform these statements to actual results.
 
Our interim consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the interim consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our interim consolidated financial statements would be affected to the extent there are material differences between these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result.  The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.
 
In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars unless otherwise state. All references to “common stock” refer to the common shares in our capital stock.
 
As used in this quarterly report, the terms, “we”, “us”, “our” and “our company” refer to Eternity Healthcare Inc. and our wholly owned subsidiary Eternity Healthcare Inc., a British Columbia corporation, unless the context clearly requires or states otherwise.
 
General Overview
 
We were incorporated in the State of Nevada on October 24, 2007 as an online services company under the name Kid’s Book Writer, Inc. On September 23, 2010, we changed our name to Eternity Healthcare Inc., and we effected a reverse split of our issued and outstanding common stock on a 10 old shares for 1 new share basis.  Our business offices are located at 8755 Ash Street, Suite 1, Vancouver, BC V6P 6T3. Our telephone number is (855) 324-1110.
 
 
15

 
 
From inception to December 13, 2010, we planned to develop a website for children to create their own books.  We intended to offer a pure online service designed to offer children and parents an ability to create their own book. Customers were to be able to log on to the service, pick a theme (i.e. birthday, family outing, vacation, special occasion such as Christmas / Easter, sporting event, summer camp, etc.), and the software would offer several options, including various book templates, backgrounds, page sizes, the ability to write your own story or have some guidance, etc.  We were unable to find sufficient financing for this business model.
 
On December 10, 2010 we entered into and completed a share exchange agreement with Eternity Healthcare Inc., a British Columbia corporation, wherein we acquired Eternity BC as our wholly owned subsidiary and abandoned our former business to focus on the operations of Eternity BC.
 
Our Current Business
 
We are a medical device company that, subject to government approval, plans to manufacture and market medical devices. Our first product to be marketed is a needle-free injection system throughout the world. The products which we hope to distribute differ from other current offerings by allowing ordinary people to perform injection of medication without the need for professionals.
 
On June 25, 2012, we entered into a marketing agreement to sell a device which does not require a needle for injection of medicine to the body from Mika Medical Company and its affiliate MK Global both of South Korea. We have the exclusive marketing rights for this device throughout North America, Germany, France and Spain and non-exclusive rights for the world market. Currently we are the sole marketer of the product.
 
The product has received regulatory approval for Europe, Canada and many other countries and US regulatory approval is underway. We plan to enter distribution agreements with several companies worldwide and enter into distribution agreements with various retailers. We plan to expand our website to include the option to purchase our products online. We anticipate producing promotional materials and advertising in medical journals as well as consumer magazines. In order to carry out these plans, we anticipate hiring a marketing manager, a quality control manager and three people for packaging and shipping. We will require approximately $1,000,000 in order to achieve these objectives and there can be no assurance that we will be able to raise the required funds.
 
On August 26, 2013, we entered into debt settlement subscription agreements pursuant to which we settled demand notes of $853,634 and $8,800 previously payable to our president and a family member, respectively. Pursuant to the agreements, we issued 1,707,268 common shares to the debt holders, in full settlement of all debt and accrued interest payable to them by our company.  The debt conversion price was $0.50 per share.
 
Concurrently with the above described issuances, we closed a private placement pursuant to which we issued 1,000,000 common shares to two investors at the price of $0.50 per share, raising aggregate proceeds of $500,000.
 
In respect of the above described transactions, we issued an aggregate of 2,724,868 common shares to four (4) non-US persons (as that term is defined in Regulation S of the Securities Act of 1933 (“Regulation S”), in offshore transactions relying on Regulation S.
 
Results of Operations for the Three Months Ended July 31, 2013 and 2012
 
The following summary of our results of operations should be read in conjunction with our unaudited interim consolidated financial statements for the quarter ended July 31, 2013 which are included herein.
 
 
16

 
 
Our operating results for the three month periods ended July 31, 2013 and 2012 and the changes between those periods for the respective items are summarized as follows:
 
   
Three Month
Period Ended
July 31, 2013
   
Three Month
Period Ended
July 31, 2012
   
Change Between
Three Month
Periods Ended
July 31, 2012
and
July 31, 2013
 
Sales
 
$
19,091
   
$
Nil
   
$
19,091
 
                         
Cost of goods sold
 
$
4,992
   
$
Nil
   
$
4,992
 
Operating expenses
 
$
96,182
   
$
29,630
   
$
66,552
 
Net loss
 
$
(82,083
)
 
$
(29,630
)
 
$
(52,453
)
 
Our expenses increased during the three month period ended July 31, 2013 compared to the same period in 2012 primarily as a result of increases in general and administrative expenses, professional fees and salaries.
 
Revenues
 
We have earned revenues of $35,266 from December 10, 2009 (date of inception) through July 31, 2013.  We have incurred $674,399 in expenses from December 10, 2009 (date of inception) through July 31, 2013.
 
Expenses
 
Our expenses for the three months ended July 31, 2013 and 2012 and for the period from December 10, 2009 (inception) through July 31, 2013 are outlined in the table below:
 
 
 
Three Month
Period Ended
July 31, 2013
($)
 
 
Three Month
Period Ended
 July 31, 2012
($)
 
 
For the Period from December 10, 2009 (Inception) through
July 31, 2013
($)
 
Depreciation
 
$
61
 
 
$
61
 
 
$
623
 
General and administrative
 
$
29,971
 
 
$
14,229
 
 
$
161,252
 
Professional fees
 
$
35,278
 
 
$
15,340
 
 
$
328,489
 
Research and development
 
$
Nil
   
$
Nil
   
$
109,360
 
Salaries
 
$
30,872
   
$
Nil
   
$
74,675
 
 
Professional Fees
 
Professional fees include accounting and auditing expenses incurred in connection with the preparation and audit of our financial statements and professional fees that we pay to our legal counsel. Our accounting and auditing expenses were incurred in connection with the preparation of our audited financial statements and unaudited interim consolidated financial statements. Our legal expenses represent amounts paid to legal counsel in connection with our corporate organization.
 
 
17

 
 
Liquidity and Financial Condition
 
Working Capital
 
 
 
At
July 31, 2013
($)
 
 
At
April 31, 2013
($)
 
Current Assets
 
$
667,185
 
 
$
189,440
 
Current Liabilities
 
$
845,467
 
 
$
767,211
 
Working Capital Deficit
 
$
(178,282
)
 
$
(577,771
)
 
Cash Flows
 
 
 
Three Month Period Ended
July 31, 2013 ($)
   
Three Month Period Ended
July 31, 2012 ($)
   
For the Period from December 10, 2009 (Inception) through
July 31, 2013 ($)
 
Cash Flows used in Operating Activities
    (94,540 )     (35,486 )     (669,137 )
Cash Flows used in Investing Activities
 
Nil
   
Nil
      (727 )
Cash Flows provided by Financing Activities
    558,970       36,109       1,311,536  
Effect of Exchange Rate Changes on Cash
    (5,316 )     (5,125 )     (26,014 )
Net Increase (Decrease) in Cash During Period
    459,144       (4,502 )     615,658  
 
As of July 31, 2013, our total assets were $667,289 and our total liabilities were $845,467 and we had a working capital deficit of $178,282. Our unaudited financial statements report a net loss of $82,083 for the three months ended July 31, 2013 compared to a net loss of $29,630 for the same period in 2012 and a net loss of $649,758 for the period from December 10, 2009 (inception) to July 31, 2013.
 
Plan of Operation
 
The following discussion of our financial condition and results of operations should be read together with our unaudited financial statements and the notes thereto included elsewhere in this filing. Our unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those anticipated in these forward-looking statements.
 
Anticipated Cash Requirements
 
We estimate that our expenses over the next 12 months (beginning August 2013) will be approximately $1,000,000 as described in the table below. These estimates may change significantly depending on the performance of our products in the marketplace and our ability to raise capital from shareholders or other sources.
 
 
18

 
 
Description
 
Estimated
Completion
Date
 
Estimated
Expenses
($)
 
Legal and accounting fees
 
12 months
   
100,000
 
Marketing and advertising
 
12 months
   
500,000
 
Employees
 
12 months
   
2,30,000
 
Consulting fees
 
12 months
   
70,000
 
Regulatory approval
 
12 months
   
20,000
 
Travel and administrative expenses
 
12 months
   
80,000
 
Total
       
1,000,000
 
 
We intend to meet our cash requirements for the next 12 months through product sales and a combination of debt financing and equity financing by way of private placements. We currently do not have any arrangements in place to complete any private placement financings and there is no assurance that we will be successful in completing any private placement financings on terms that will be acceptable to us. We may not raise sufficient funds to fully carry out our business plan.
 
Going Concern
 
The interim consolidated financial statements accompanying this report have been prepared on a going concern basis, which implies that our company will continue to realize its assets and discharge its liabilities and commitments in the normal course of business. Our company has not generated revenues since inception and has never paid any dividends and is unlikely to pay dividends or generate earnings in the immediate or foreseeable future. The continuation of our company as a going concern is dependent upon the continued financial support from our shareholders, the ability of our company to obtain necessary equity financing to achieve our operating objectives, and the attainment of profitable operations. As of July 31, 2013, our company has accumulated losses of $649,758 since inception. We do not have sufficient working capital to enable us to carry out our stated plan of operation for the next twelve months. These interim consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should our company be unable to continue as a going concern.
 
Our interim consolidated financial statements contain additional note disclosures describing the circumstances related to the uncertainty of our ability to continue as a going concern.
 
The continuation of our business is dependent upon us raising additional financial support. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.
 
Future Financings
 
We anticipate continuing to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to our existing stockholders. There is no assurance that we will achieve any additional sales of our equity securities rearrange for debt or other financing to fund our planned activities.
 
Off-Balance Sheet Arrangements
 
We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.
 
 
19

 
 
Critical Accounting Policies
 
The interim consolidated financial statements of our company have been prepared in accordance with generally accepted accounting principles in the United States. Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgment.
 
The following is a summary of significant accounting policies used in the preparation of these consolidated financial statements.
 
Basis of Presentation
 
These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in U.S. dollars.
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of our company and our wholly-owned subsidiary, Eternity BC.  All significant intercompany balances and transactions have been eliminated in consolidation.
 
Cash and Cash Equivalents
 
Cash and cash equivalents include highly liquid investments with original maturities of three months or less.
 
Inventory
 
Inventory is stated at the lower of cost or market with cost determined under the weighted average cost method
 
Foreign Currency Translation
 
Our company’s functional currency is the Canadian dollar and reporting currency is the U.S. dollar.  All transactions initiated in other currencies are translated into the reporting currency in accordance with ASC 830, “Foreign Currency Matters” as follows:
 
 
iii)
Assets and liabilities at the rate of exchange in effect at the balance sheet date; and
 
iv)
Revenue and expense items at rate of exchange at the dates on which those elements are recognized.
 
Gains and losses on translation are included in other comprehensive income (loss) in stockholders’ deficiency for the period.
 
Basic and Diluted Net Income (Loss) Per Share
 
Our company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share”.  ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement.  Basic EPS is computed by dividing net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period.  Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method.  In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.  Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
 
 
20

 
 
Use of Estimates
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenditures during the reporting period. Actual results could differ from these estimates.
 
 
As a “small reporting company”, we are not required to provide the information required by this Item.
 
 
Management’s Report on Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and principle accounting officer) to allow for timely decisions regarding required disclosure.
 
As of the end of our quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and principle accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our chief executive officer and chief financial officer (our principal executive officer, principal financial officer and principle accounting officer) concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this quarterly report due to the material weaknesses in our internal controls over financial reporting identified in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on August 8, 2013.
 
Changes in Internal Control over Financial Reporting
 
During the period covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 
 
We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.
 
 
As a “small reporting company”, we are not required to provide the information required by this Item.
 
 
21

 
 
 
On August 26, 2013, we entered into debt settlement subscription agreements pursuant to which we settled demand notes of $853,634 and $8,800 previously payable to our president and a family member, respectively. Pursuant to the agreements, we issued 1,707,268 common shares to the debt holders, in full settlement of all debt and accrued interest payable to them by our company.  The debt conversion price was $0.50 per share.
 
Concurrently with the above described issuances, we closed a private placement pursuant to which we issued 1,000,000 common shares to two investors at the price of $0.50 per share, raising aggregate proceeds of $500,000.
 
In respect of the above described transactions, we issued an aggregate of 2,724,868 common shares to four non-US persons (as that term is defined in Regulation S of the Securities Act of 1933 (“Regulation S”), in offshore transactions relying on Regulation S.
 
 
None.
 
 
Not applicable.
 
 
None.
 
 
22

 
 
 
Exhibit
No.
 
Document Description
     
(2)
 
Plan of acquisition, reorganization, arrangement, liquidation or succession
2.1
 
Share Exchange Agreement with Eternity Healthcare Inc., dated December 13, 2010 (incorporated by reference to our Current Report on Form 8-K filed on December 17, 2010)
(3)
 
(i) Articles of Incorporation; (ii) By-laws
3.1
 
Articles of Incorporation (incorporated by reference to our C Registration Statement on Form S-1 filed on June 25, 2008)
3.2
 
By-laws (incorporated by reference to our Registration Statement on Form S-1 filed on June 25, 2008)
3.3
 
Certificate of Amendment filed with the Nevada Secretary of State on November 1, 2010 (incorporated by reference to our Current Report on Form 8-K filed on November 16, 2010)
(10)
 
Material Contracts
10.1
 
Revised Distribution Agreement dated June 25, 2012 between our company, our subsidiary, MK Global Co. and MIKA Medical Co. (incorporated by reference to our Annual Report on Form 10-K filed on July 19, 2012)
10.2
 
2013 Stock Option Plan (incorporated by reference to our Annual Report on Form 10-K filed on August 8, 2013)
10.3
 
Rental Agreement dated June 22, 2013 between our company and Kinexus Bioinformatic (incorporated by reference to our Annual Report on Form 10-K filed on August 8, 2013)
(14)
 
Code of Ethics
14.1
 
Code of Business Conduct and Ethics (incorporated by reference to our Annual Report on Form 10-K filed on August 8, 2013)
(31)
 
Rule 13a-14(a)/15d-14(a) Certifications
31.1*
 
Section 302 Certifications under Sarbanes-Oxley Act of 2002
(32)
 
Section 1350 Certifications
32.1*
 
Section 906 Certifications under Sarbanes-Oxley Act of 2002
101**
 
Interactive Data File (Form 10-K for the year ended April 30, 2012 furnished in XBRL)
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document

*
Filed herewith.
   
**
Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.
 
 
23

 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
ETERNITY HEALTHCARE INC.
 
 
Date:  September 16, 2013
/s/ Hassan Salari
 
Hassan Salari
 
President, Chief Executive Officer,
Chief Financial Officer, Secretary, Treasurer and Director
 
(Principal Executive Officer,
Principal Financial Officer and Principal Accounting Officer)
 
 
 24